A number of things remain to be clarified, such as i) whether other DENV-susceptible cells produce vesicles containing viral proteins, ii) the differences in EVs composition according to post infection periods or infecting serotype, iii) the effects of specific miRNAs transported by EVs from infected cells, and iv) the ability of NS3-positive EVs to activate antigen-presenting cells or T or B lymphocytes. The gene discussed is KRAS; the disease is infection.